Application | Comment | Organism |
---|---|---|
drug development | HIV-1 reverse transcriptase is a major target of antiviral therapy | Human immunodeficiency virus 1 |
medicine | HIV-1 reverse transcriptase is a major target of antiviral therapy | Human immunodeficiency virus 1 |
Cloned (Comment) | Organism |
---|---|
recombinant expression of His-tagged subtype B HIV-1 reverse transcriptase in Escherichia coli strain M15 | Human immunodeficiency virus 1 |
recombinant expression of His-tagged subtype C HIV-1 reverse transcriptase in Escherichia coli strain M15 | Human immunodeficiency virus 1 |
Protein Variants | Comment | Organism |
---|---|---|
M184V | the fidelity of DNA polymerization of the mutant HIV-1 RT is significantly higher than that of wild-type enzyme | Human immunodeficiency virus 1 |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one | - |
Human immunodeficiency virus 1 | |
Etravirine | - |
Human immunodeficiency virus 1 | |
lamivudine | - |
Human immunodeficiency virus 1 | |
additional information | comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview | Human immunodeficiency virus 1 | |
nevirapine | - |
Human immunodeficiency virus 1 | |
Tenofovir | - |
Human immunodeficiency virus 1 | |
tenofovir diphosphate | - |
Human immunodeficiency virus 1 | |
zidovudine | - |
Human immunodeficiency virus 1 |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
Mg2+ | required | Human immunodeficiency virus 1 |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
51000 | - |
1 * 66000 + 1 * 51000, SDS-PAGE | Human immunodeficiency virus 1 |
66000 | - |
1 * 66000 + 1 * 51000, SDS-PAGE | Human immunodeficiency virus 1 |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
deoxynucleoside triphosphate + DNAn | Human immunodeficiency virus 1 | - |
diphosphate + DNAn+1 | - |
? | |
deoxynucleoside triphosphate + DNAn | Human immunodeficiency virus 1 M01 | - |
diphosphate + DNAn+1 | - |
? | |
deoxynucleoside triphosphate + DNAn | Human immunodeficiency virus 1 BG05 | - |
diphosphate + DNAn+1 | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Human immunodeficiency virus 1 | AF324493 | subtype B | - |
Human immunodeficiency virus 1 | Q8Q2U5 | subtype C | - |
Human immunodeficiency virus 1 | Q8Q2V9 | subtype C | - |
Human immunodeficiency virus 1 BG05 | Q8Q2U5 | subtype C | - |
Human immunodeficiency virus 1 M01 | Q8Q2V9 | subtype C | - |
Posttranslational Modification | Comment | Organism |
---|---|---|
proteolytic modification | p66/p51 heterodimer formation through protease cleavage | Human immunodeficiency virus 1 |
Purification (Comment) | Organism |
---|---|
recombinant His-tagged subtype B HIV-1 reverse transcriptase in heterodimeric form from Escherichia coli strain M15 by metal affinity chromatography and ion exchange chromatography to homogeneity | Human immunodeficiency virus 1 |
recombinant His-tagged subtype C HIV-1 reverse transcriptase in heterodimeric form from Escherichia coli strain M15 by metal affinity chromatography and ion exchange chromatography to homogeneity | Human immunodeficiency virus 1 |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
deoxynucleoside triphosphate + DNAn | - |
Human immunodeficiency virus 1 | diphosphate + DNAn+1 | - |
? | |
deoxynucleoside triphosphate + DNAn | - |
Human immunodeficiency virus 1 M01 | diphosphate + DNAn+1 | - |
? | |
deoxynucleoside triphosphate + DNAn | - |
Human immunodeficiency virus 1 BG05 | diphosphate + DNAn+1 | - |
? | |
dTTP + DNAn | - |
Human immunodeficiency virus 1 | diphosphate + DNAn+1 | - |
? | |
dTTP + DNAn | - |
Human immunodeficiency virus 1 M01 | diphosphate + DNAn+1 | - |
? | |
dTTP + DNAn | - |
Human immunodeficiency virus 1 BG05 | diphosphate + DNAn+1 | - |
? | |
additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-) ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 | ? | - |
? | |
additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-) ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview.. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 | ? | - |
? | |
additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-)ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 | ? | - |
? | |
additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-) ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview.. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 M01 | ? | - |
? | |
additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-) ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 BG05 | ? | - |
? |
Subunits | Comment | Organism |
---|---|---|
dimer | 1 * 66000 + 1 * 51000, SDS-PAGE | Human immunodeficiency virus 1 |
More | p66/p51 heterodimer formation through protease cleavage. Although p51 provides RT with essential structural and conformational stability, p66 is the catalytically active subunit and includes the N-terminal polymerase domain (residues 1-321) and C-terminal RNase H domain (residues 441-560), linked by a connection domain | Human immunodeficiency virus 1 |
Synonyms | Comment | Organism |
---|---|---|
HIV-1 reverse transcriptase | - |
Human immunodeficiency virus 1 |
HIV-1 RT | - |
Human immunodeficiency virus 1 |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Human immunodeficiency virus 1 |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.8 | - |
assay at | Human immunodeficiency virus 1 |
General Information | Comment | Organism |
---|---|---|
additional information | although p51 provides RT with essential structural and conformational stability, p66 is the catalytically active subunit and includes the N-terminal polymerase domain (residues 1-321) and C-terminal RNase H domain (residues 441-560), linked by a connection domain | Human immunodeficiency virus 1 |